Objectives: Pelvic muscle tenderness occurs often in patients with urologic chronic pelvic pain syndrome; symptoms frequently can be reduced with pelvic myofascial physical therapy. This open-label pilot study evaluated the safety of a personal wand that enables patient's self-treatment of internal myofascial trigger points in the pelvic floor and its effect in reducing pelvic muscle tenderness.
P atients with urologic chronic pelvic pain syndrome (UCPPS) including chronic prostatitis/chronic pelvic pain syndrome, painful bladder syndrome/interstitial cystitis, and isolated orchalgia are often difficult to treat as their pain symptoms often do not respond to standard pharmaceutical or any surgical treatment. UCPPS patients often report pain associated with palpation of internal and external pelvic muscles. 1 In men, this pain does not necessarily originate from the prostate, which has been a long held but erroneous concept. Instead, much of this pain emanates from myofascial trigger points (TrPs) that when palpated are tender and reproduce the specific anatomic location of pain described by the patient. 2 TrPs are defined as hyperirritable areas in skeletal muscles that are associated with palpable nodules in taut bands of muscle fiber. 3 TrPs may refer pain either locally or to another location in the body along a nerve pathway. Quantitative asymmetry in muscle tone (increased tension) in myofascial TrPs has been shown with magnetic resonance elastography imaging and by observing alterations in the biochemical milieu of inflammatory mediators of active or latent TrPs. 4, 5 Active TrPs can cause a spectacular amount of discomfort for the patient. Manual palpation or compression of a tender TrP elicits local discomfort or pain, referred pain or a "jump" or twitch response. No known pathogenic mechanisms involving inflammation or other molecular process explain the basis of this myoneuropathic disorder. Evidence suggests that the pain originates within the muscle tissue itself and that chronic myofascial tension also plays a major role in chronic prostatitis/chronic pelvic pain syndrome and TrPs produce pain in fibromyalgia. 6, 7 External and internal pelvic manual physical therapy (PT) has been reported to be successful in alleviating a significant proportion of patient's discomfort over time in patients with UCPPS. [8] [9] [10] Although frequent and intensive PT is helpful, it is time consuming, labor intensive, and costly. Our group has developed an immersion protocol involving intensive PT coupled with specific relaxation training for relief of chronic, refractory pelvic pain. 11 We teach patients to treat themselves using muscle stretching, external and internal TrP release, and relaxation exercises daily at home. We now have extended our efforts to also train patients in internal self-treatment through the use of a personal therapeutic wand designed to provide internal release of painful pelvic TrPs thereby replacing the need for regular manual PT. This report describes a clinical trial to evaluate the safety of this therapeutic device and its effectiveness in decreasing the pain and sensitivity of pelvic muscles.
MATERIALS AND METHODS
This prospective, open-label, pilot study was reviewed and approved by an Ethical Review Board and designated as a nonsignificant risk clinical trial. Signed informed consent was obtained from all patients. Patients with UCPPS who referred themselves for an intensive 6-day PT and relaxation therapy program were invited to participate. Men and women with any UCPPS were considered for inclusion without regard to empirical genitourinary diagnosis. All patients underwent baseline urologic or gynecologic evaluation to rule out other treatable conditions and only those demonstrating muscle-related pain were eligible for inclusion. Patients were excluded if they did not have muscle-based pelvic pain, were not found to have internal TrPs painful to palpation, or were deemed not competent in using the wand. There was no cost to the patient for the experimental wand device. The protocol was designed to ensure proper and consistent use of the therapeutic device and required careful, initial patient evaluation for educability regarding the myofascial basis of painful TrPs and the patient's ability to follow specific instructions and treatment techniques to assure safety.
Throughout the course of this study, the patients were instructed to continue using the external muscle massage and stretching techniques and home progressive relaxation exercises that they learned in the intensive 6-day training program. No modifications were to be made in any prescription or over-the-counter medications. Figure 1 illustrates the therapeutic wand. It is solid, 3.2 cm in diameter, made of ultem plastic with a distal shepherd's crook curve, and 1.9 cm nitrile rubber tip that allows the patient to insert a predetermined but limited length into the rectum or vagina. A moveable guard prevents further advancement. The wand serves as an extended finger that is easily navigated inside the pelvis. It is used to locate and release painful internal myofascial TrPs. The algometer sensor is easily visible and allows same time monitoring of point pressure to prevent excessive or dangerous force. The surface area of the terminal ball that is applied to the tissue surface is 1.91 cm 2 (0.75 inch 2 ) and the pressure gauge integrated with the wand tip provides numerical readings that correspond to applied torque pressure in the range of 0 to 2 kg/cm 2 . If a maximum pressure were to be applied, it would equal to 8.7 psi or 0.62 kg/cm 2 . Patients were instructed not to exceed readout values greater than 0.34 kg/cm 2 and were trained to massage their own pelvic musculature without causing rectal or vaginal tissue trauma. They were also instructed to never apply pressure that elicited neurologic stimulation such as tingling, pulsation, or radiated pain such as sciatica. Per protocol, the wand manipulations were to be performed on a regular basis, typically 3 to 4 times per week, approximately 5 to 10 minutes during each session to release the pelvic floor from active painful trigger points and areas of myofascial tenderness and restriction. The average amount of pressure that patients applied to single or multiple TrPs was recorded at the initiation of therapy and again assessed after 1 and 6 months of wand usage. Patient education included a description of internal muscles, bladder, cervix, uterus, and prostate anatomy. A pelvic model was used to facilitate this teaching. The physical therapist (T.S.) created individualized drawings to map specific tender TrPs for each patient and the patient was instructed on the appropriate methods of wand insertion and safe pressure application. Patients used a water-based lubricated, vinyl or nitrile glove over the wand tip; the anus or vaginal introitus was also lubricated with a water-based gel. Care was taken to avoid any tissue dryness or resistance during insertion of the wand. Figure 2 shows the recommended patient position, supine with back and head elevated 45 degrees to palpate prostate and anterior TrPs. The patient is instructed to lie on his side for palpation of lateral and posterior TrPs.
Men were taught the anatomic location of the prostate. Brief gentle pressure is applied initially to help the patient make the distinction between the prostate and the tissue surrounding it in which TrPs typically are found. Patients were assisted in localizing their own TrPs by using the pelvic map specifically generated for them, beginning at FIGURE 1. Illustration of the therapeutic wand and electrical pressure readout device.
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Internal Myofascial TrP Wand for UCPPS 1 and 11 o'clock and working to the posterior region. After identification of deep TrPs, the patient was instructed to slowly withdraw the wand in increments of 1 =2 inch to recheck at a shallower depth; this was to be repeated to the point of wand removal. Women were instructed to use both vaginal and rectal wand insertion to determine optimal effectiveness. The glove covering on the tip of the wand was replaced when changing from vaginal to rectal self-treatment or vice versa. Gradual increased pressure on each TrP started with a 10 to 12-second gentle motion technique to identify the precise trigger point and then 15 to 90-second static holding pressure until tenderness around the TrP abated. Acute flare-ups of pain were expected during the initial therapeutic maneuvers as it occurs frequently in manual treatment performed by a physical therapist or physician. However, patients were discouraged from inducing further discomfort or pain beyond a 5 to 7 on a pain visual analog scale (VAS; 0 to 10). For continued therapy, patients were instructed to lubricate and gently stretch the rectal or vaginal opening before insertion of the wand and to reduce by half or less the pressure on the readout of the display. Instruction for home usage of the wand was provided and patients were checked up to 3 times for clarifications by the physical therapist before discharge from the clinic. Any trace bleeding was to be promptly reported and the manual therapy discontinued for several days. In the event of continued bleeding, patients were required to have a physician evaluation and follow up.
Assessments
Adverse events were to be documented and followed to resolution as needed. Patients' perceptions of pain sensitivity of TrPs before wand use and after 1 and 6 months were reported with a 10-point VAS (10 being greatest pain sensitivity). Changes in sensitivity were compared using the Wilcoxon matched-pairs signed-ranks test. P values r0.05 were considered statistically significant. Statistical results were derived using Stata/SE 10.1 (StataCorp, College Station, TX). An outcome survey was administered by telephone interview or written questionnaire at 1 and 6 months after onset of wand use. Table 1 shows an abbreviated version of the survey. Survey responses are reported as proportions or as medians with interquartile range (25th and 75th percentiles) values. Inferences on the effectiveness of the wand for pain reduction relative to change in TrP sensitivity VAS scores were compared with the Kruskal-Wallis test.
Patients' assessment of the effectiveness of the device in alleviating their pain and satisfaction with its use were collected at 1 and 6 months after treatment. S Likert type scale of 1 to 3 (1=very effective/satisfied, 2=moderately effective/satisfied, and 3=not effective/satisfied) was used.
RESULTS
A total of 157 patients were eligible for the study; they were enrolled from October 2008 to mid-December 2009 with intention to obtain a 6-month follow-up. A total of 113 patients (72%) including 106 men and 7 women completed 6 months of wand use by December 2009. Table 2 lists the 44 patients withdrawn from the study; 3 before the 1-month evaluation and 41 before the 6-month evaluation for a variety of reasons including noncompliance with use of the wand at least once weekly (10 of 44), failure to complete questionnaires (10 of 44), or prematurely discontinued for a variety of reasons.
No withdrawals were because of adverse events. For the 113 patients, the median age was 41 years (range: 32.5 to 52.5 y). The median number of TrPs palpated in each patient was 6 (range: 4 to 6.5).
Safety Assessments
There were no serious adverse events. Transient adverse events of minor severity were reported by 15 patients including 12 with transient anal soreness and increased sensitivity of TrPs. Two patients had 1 incident of trace urethral bleeding believed to be originating from the prostate; another patient with slight rectal bleeding was known to have hemorrhoids. No incident required discontinued use of the wand nor required any medical treatment. Thirty participants reported some mechanical difficulties with the algometer reading, battery issues, or the calibration of pressure sensor. These technical difficulties occurred in the early iteration of the circuit board measuring pressure of the wand tip and were resolved with a telephone conversation or replacement of the wand.
Pelvic Muscle TrP Sensitivity
Pelvic muscle TrP sensitivity data before and after wand therapy was available for 111 patients at 1 month (2 patients had missing data) and 109 at 6 months (4 patients had missing data). The median sensitivity before wand use was 7.5 on a scale of 1 to 10 (range: 6 to 8.5); it decreased significantly after 1 month of wand use to a median of 5 (range: 4 to 6.5; P<0.001). At 6 months, the median sensitivity decreased further to 4 (range: 2.5 to 5.5), representing a median difference in sensitivity of 2.5 (range: 1.5 to 4) compared with pretreatment (P<0.001); 87% (95 of 109) had at least some reduction in sensitivity after 6 months; Figure 3 depicts these results graphically as box plots. Notably, 95% (106 of 111; 2 did not respond) of patients described the wand as very (n=44) or moderately effective (n=62) in alleviating pain after 6 months of use. Those describing the wand as very effective had a median decline in TrP sensitivity VAS score of 5, compared with a median decline of 2 for those stating a moderately effective response or a median decline of 1 in those saying the wand was not effective (P<0.001). Satisfaction with using the wand including ease of use and monitoring pressure was described as very satisfactory by 53% (58 of 110; n=3 missing) and moderately satisfactory by 40% (44 of 110).
DISCUSSION
The pain associated with UCPPS can substantially affect a patient's quality of life. Some progress exists in identifying phenotypes of these pelvic disorders that leads to selection of the most appropriate and effective use of multimodal therapy. 12 Pelvic muscle tenderness is associated with more than 50% of the reported phenotypes and patients with more than 1 phenotype typically have higher pain scores. It has also been proposed that above-average pain sensitivity is a risk factor for the development of chronic pain disorders. 13 Uncontrolled trials of myofascial release therapy have shown that specific neuromuscular targets may offer favorable therapeutic avenues. Intensive initial physiotherapy using TrP release techniques coupled with specific relaxation training has been shown to be a viable therapeutic modality in our hands, both for pain relief and improvement in male sexual dysfunction.
14 These combined interventions represent a medical therapy based upon a biopsychosocial model; a form of physical and psychological treatment of the musculoskeletal and autonomic nervous systems. This therapy results in pain reduction or abatement. Furthermore, this approach avoids the use of systemic pharmaceutical agents and any surgical invasion. The introduction of the therapeutic wand to our treatment protocol serves as an accessible and convenient tool for enhancing patient treatment.
The personal therapeutic wand was shown to be safe in patients adequately trained in its use and helped to achieve pain reduction or abatement in most patients thus ranking it very high amongst other multimodal treatments. Patients required simple education regarding hygiene and the careful application of the wand to prevent trauma to the anal or vaginal tissue. We were encouraged by the minimal lowgrade mucosal bleeding that was reported by only 3 patients. This study shows that the therapeutic wand is associated with a significant reduction in pelvic muscle sensitivity. Patient ability to self-administer internal TrP release has an obvious benefit by eliminating the need for frequent conventional PT office visits. In addition, this wand makes internal TrP release available for the many pelvic pain patients who have no access to competent internal PT. We suggest that this wand device may potentially lend itself to provide more objective measurements of pelvic pain using pressure readings and time-observed clinical response to any other form of therapy. Furthermore, providing physicians with this type of therapeutic device allows them to prescribe this therapy with patient referral to a qualified physical therapist for teaching and support, thus involving the patients in independent use of the wand at home as 1 component of the entire treatment protocol.
Limitations of the study included the fact that patients enrolled in the study were those qualified self-selected individuals who were seeking help in reducing their pain and symptoms after failing traditional multimodal therapy. In addition, 6 months of follow up requires a motivated patient as participants were encouraged to use the wand diligently, more than once per week, and it is likely that patients achieving amelioration of pain would continue using the device. Consequently, the effect of wand usage in less-diligent patients is unknown. On account of the referral patterns for patients to our immersion therapy clinics, we have a predominance of male patients enrolled in the study. There were too few women completing 6 months of wand use to draw any meaningful conclusions about outcomes in this small subset of participants. Although 17 women enrolled, only 7 completed the study, some for the reason that they believed internal pelvic massage could be easily accomplished with the finger and they did not need the wand. We lacked a sham control group, however, it would be difficult to safely implement a protocol where patients would palpate internal pelvic floor areas not associated with TrPs and patients who have failed prior therapies would likely be unwilling to chance a sham treatment. No standardized pain symptom scores were collected but it has been well established that pain sensitivity is an issue of individual patient perception can be assessed by self-rating. 13 The pain sensitivity VAS accomplished the patient self-assessments. Patients predominantly came from distant locations and were not available for personal examination follow-up, thus requiring telephone or questionnaire evaluations at the predetermined endpoints. The lack of patient proximity also prevented the evaluation of transient episodes of trace prostate and rectal bleeding with endoscopy. However, in the 3 cases in which this occurred, patients stated that the event resolved within a couple of days and did not cause anyone to discontinue use of the wand. A final limitation is that patients were instructed in therapies including combined relaxation methods and palpation of external TrPs which are integral to our multimodal therapy in the immersion clinic. Introduction of the wand for palpation of TrPs by the patient was to encourage continued self-treatment and we anticipated that this additional element would likely result in greater pain relief in compliant patients. A different study design that can build upon this pilot study is needed to better delineate how other therapies influence the relationship between wand use and TrP sensitivity.
CONCLUSIONS
This study shows that a protocol of proper training, education, and professional supervision provides safety and efficacy for UCPPS patients to perform their own internal TrP release using an internal therapeutic wand. The wand was associated with greater than a 25% perceived reduction in TrP sensitivity in 77% of patients after 6 months with a reported moderate-to-marked satisfaction with wand use in 93%. Future studies are needed within larger and varied pelvic pain patients. Patient involvement in a supervised protocol that allows utilization of a therapeutic wand for myofascial TrP release seems to be a viable management option to reduce TrP sensitivity.
